[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader
A J
AJ
Klinik für Urologie und Kinderurologie, Universitätsklinikum Giessen und Marburg GmbH, Baldingerstrasse, 35033 Marburg. ajschrader@gmx.de
Hegele
A
A
Olbert
P
P
Buer
J
J
Jeron
A
A
Hofmann
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D000077157:Sorafenib; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology; D019139:Tumor Escape / Q000187:drug effects / Q000276:immunology
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib